Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 8/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 4/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20530026 | 0.94 | ALB (0.53) | ALBCA9TLR2KMT2AMDM2 | |
| SCHEMBL31298693 | 0.92 | ALB (0.48) | ALBCA9TLR2GLP1R | |
| SCHEMBL20530037 | 0.90 | ALB (0.47) | ALBCA9TLR2GLP1RMDM2 | |
| SCHEMBL31298675 | 0.90 | ALB (0.47) | ALBCA9TLR2GLP1RMDM2 | |
| SCHEMBL31298701 | 0.90 | CPB1 (0.45) | ALBTLR2CPB1CPB2GLP1R | |
| SCHEMBL30895420 | 0.86 | KMT2A (0.52) | TLR2GLP1RKMT2AMDM2 | |
| SCHEMBL30895594 | 0.86 | TLR2 (0.50) | TLR2CPB1CPB2KMT2AMDM2 | |
| SCHEMBL29521884 | 0.85 | TLR2 (0.41) | ALBTLR2MDM2 | |
| SCHEMBL29521888 | 0.85 | ALB (0.44) | ALBCA9TLR2KMT2AMDM2 | |
| SCHEMBL31298676 | 0.85 | TLR2 (0.44) | TLR2CPB1CPB2CALCRLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025029608-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |